Compare GoPro Inc (GPRO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GoPro Inc vs 10X Genomics Inc — how do they compare? GoPro Inc trades at $1.19 (market cap $243.50M), while 10X Genomics Inc trades at $82.23 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 41.4× GoPro Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and 10X Genomics Inc for 92 Days on average.
| GPRO | TXG | |
|---|---|---|
Market Cap | $243.50M | $10.07B |
Volume | 11,527,160 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $2.35 | $97.74 |
52-Week Low | $0.58 | $11.48 |
Typical Hold Time | 45 Days | 92 Days |
Enterprise Value | $302.28M | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, as the company faces significant financial challenges with negative net income margins and declining revenues. Despite recent product recognition for its MISSION 1 series, the stock has been volatile amid merger discussions with Starman Optical and influencer investment interest. Technical indicators show a bullish moving average signal but mixed oscillators, while fundamentals reveal persistent losses and cash burn.
The outlook remains highly speculative with a proposed $1.14 per share buyout offering a potential floor, but ongoing losses and competitive pressures pose substantial risks. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's turnaround prospects despite recent merger excitement.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
